Evaluation of Edoxaban in Anticoagulant Naïve Patients With Nonvalvular Atrial Fibrillation (NVAF) and High Creatinine Clearance
Evaluation of Edoxaban in Anticoagulant Naïve Patients With Nonvalvular Atrial Fibrillation (NVAF) and High Creatinine Clearance
Atrial fibrillation is when the heart's two upper chambers (called atria) beat chaotically and irregularly, out of coordination with the two lower chambers (called ventricles) of the heart. This can lead to blood clots forming in the heart chamber.
Patients with atrial fibrillation will be treated with either 60 mg or 75 mg of edoxaban for up to 12 months, with a 2-4 week follow-up, after which their participation is complete.
Blood samples will be collected before the first dose of study drug (Day 0), and on Days 30, 90 and 360 (at pre dose, 1-2 hours post dose and 4-8 hours post-dose).
Inclusion Criteria:
Exclusion Criteria:
Has history or current use of over-the-counter medications, dietary supplements, or drugs (including nicotine and alcohol) outside protocol-specified parameters
Has signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise:
Copenhagen S, 2300, Denmark
Kaunas, LT-50009, Lithuania
Gdynia, 81-157, Poland
Lodz, 93-153, Poland
Kemerovo, 650002, Russia
Moscow, 121522, Russia
Saint Petersburg, 194044, Russia
Ivano-Frankivsk, 76018, Ukraine
Kharkiv, 61103, Ukraine
Kharkiv, 61176, Ukraine
Lutsk, 43024, Ukraine
Uzhhorod, 88000, Ukraine